gefitinib
information and resources from the National Cancer Institute
gefitinib
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. gefitinib
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
|
|
|
|
news articles
American Journal of Respiratory and Critical Care Medicine Vol 173 ... Mar 28, 2006
AJRCCM (subscription), Gefitinib (Iressa) was the first in its class to receive US Food and Drug Administration (FDA) approval in the United States and Japan, but the approval was ...
Two New Cancer Drugs Discovered Mar 28, 2006
Medical News Today (press release), Growth Factor Receptors (EGFR), which are targeted by other successful agents such as trastuzamab (Herceptin), cetuximab (Erbitux) and gefitinib (Iressa). ...
Genome Studies Expose Cancer's Weak Side Mar 14, 2006
eMaxHealth.com, Meanwhile, independent clinical trials were underway to study gefitinib, a new, targeted drug that inhibits the signaling activity of EGFR. ...
Oncologists Jumped Gun on Taxanes After Oral Presentation Mar 17, 2006
MedPage Today, They cited the case of Iressa (gefitinib), where preliminary results presented at a meeting did not stand up in a large placebo-controlled trial. ...
Study Finds Shifts In Treatment Trends Prior To Publication Of ... Mar 17, 2006
Medical News Today (press release), They present the story of Iressa (gefitinib), a drug used for treating lung cancer, prescribed based on early studies that didn't have control groups and that ...
Dana Reeve, a Nonsmoker, Dies of Lung Cancer at 44 Mar 7, 2006
MedPage Today, Patients with mutations in the EGF receptor may respond to two targeted therapies, Tarceva (erlotinib) and Iressa (gefitinib), a finding that was reported by Dr ...
New Therapies Target Cancer Mar 7, 2006
Drug Discovery & Development (subscription), A number of other targeted kinase therapies came in the wake of Gleevec, including Iressa (gefitinib) from AstraZenenca Pharmaceuticals, Wilmington, Del ...
Results Encouraging with Interferon Alpha Plus Iressa (Gefitinib) ... Nov 22, 2005
DG News PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in patients ...
Iressa Has Little Effect on Advanced Breast Cancer: Presented at ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- Hormone-resistant breast cancers do not appear to respond to treatment with Iressa (gefitinib), according to results of ...
New Data Show Survival Benefit for Arimidex(TM) in Early Breast ... Dec 9, 2005
news aktuell (Pressemitteilung), CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed) and 'IRESSA' (gefitinib) as well as a ...
|
|
